Division of Gastroenterology and Hepatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA.
VA Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, USA.
Am J Gastroenterol. 2024 Oct 1;119(10):2130-2133. doi: 10.14309/ajg.0000000000002834. Epub 2024 Apr 29.
Cannabis may provide inflammatory bowel disease (IBD) patients with an alternative to opioids for pain.
We conducted a difference-in-difference analysis using MarketScan. Changes over time in rates of opioid prescribing were compared in states with legalized cannabis to those without.
We identified 6,240 patients with IBD in states with legalized cannabis and 79,272 patients with IBD in states without legalized cannabis. The rate of opioid prescribing decreased over time in both groups and were not significantly different (attributed differential = 0.34, confidence interval -13.02 to 13.70, P = 0.96).
Opioid prescribing decreased from 2009 to 2016 among patients with IBD in both states with legalized and state without legalized cannabis, similar to what has been observed nationally across a variety of diseases. Cannabis legalization was not associated with a lower rate of opioid prescribing for patients with IBD.
大麻可能为炎症性肠病（IBD）患者提供了一种替代阿片类药物的疼痛治疗方法。
我们使用 MarketScan 进行了差异分析。比较了大麻合法化州和非大麻合法化州的阿片类药物处方率随时间的变化。
我们在大麻合法化的州识别出 6240 名 IBD 患者，在非大麻合法化的州识别出 79272 名 IBD 患者。两组的阿片类药物处方率随时间呈下降趋势，且无显著差异（归因差异 = 0.34，置信区间 -13.02 至 13.70，P = 0.96）。
在大麻合法化和非合法化的州，IBD 患者的阿片类药物处方率从 2009 年到 2016 年都呈下降趋势，这与在各种疾病中全国范围内观察到的情况相似。大麻合法化与 IBD 患者阿片类药物处方率降低无关。
